New therapeutic target expands options for multiple myeloma
August 04, 2026
August 04, 2026
PHILADELPHIA, Pennsylvania, Aug. 4 -- The University of Pennsylvania posted the following news:
* * *
New therapeutic target expands options for multiple myeloma
*
In a phase I clinical trial, treatment with the investigational bispecific antibody cevostamab has reduced cancer in more than 40% of patients with multiple myeloma. Many of the patients had already been through multiple other cancer treatments, and produced a median duration of resp . . .
* * *
New therapeutic target expands options for multiple myeloma
*
In a phase I clinical trial, treatment with the investigational bispecific antibody cevostamab has reduced cancer in more than 40% of patients with multiple myeloma. Many of the patients had already been through multiple other cancer treatments, and produced a median duration of resp . . .